Accessing this content is a benefit of AAGL Membership
To continue, please log into your AAGL membership account:

AAGL Username



Click on the poster above to navigate to the next slide

You are here: Home From the Desk of the President – FDA Announces Decision on Transvaginal Surgical Mesh

From the Desk of the President – FDA Announces Decision on Transvaginal Surgical Mesh

FDA takes action to protect women’s health, orders manufacturers of surgical mesh intended for transvaginal repair of pelvic organ prolapse to stop selling all devices

Yesterday April 16, 2019, the U.S. Food and Drug Administration issued an order to the manufacturers of all remaining transvaginal surgical mesh products for POP repair to immediately stop selling and distributing their product in the U.S. These manufacturers and their products are:

This action is a result of the FDA’s series of escalating safety actions related to transvaginal mesh over the past several years, beginning in July 2011 with an FDA Safety Commutation, then to the January 2016 reclassification of these devices to the highest risk class (class III), and concluding with the February 2019 advisory committee meeting which precipitated this decision. The companies now have 10 days to inform the FDA of their plan on how they will remove these products from the market; however, they are still required to continue the studies they have been conducting since 2016 with follow-up of enrolled subjects who have received these transvaginal mesh products for the POP repair.

What does this mean for your patients that have had transvaginal mesh placed previously? Patients should continue with their normal annual care routine in regard to their POP repair. If they are not having any complications or symptoms, nothing additional needs to be done. If they are experiencing complications or symptoms, they should discuss other treatment options with you and/or their other gynecologic health care provider.

What does this mean for you? Since these transvaginal mesh products will no longer be available on the market, you’ll need to begin discussing alternate treatment options for your patients that require surgical repair of POP.

Please note: midurethral slings and mesh for sacrocolpopexy are not included in this recommendation, so it is important that there are no misunderstandings regarding this communication.  Sling devices and sacrocolpopexy mesh implants will remain on the U.S. market.

I encourage you to read the entire FDA announcement by clicking on the button below.


Marie Fidela R. Paraiso
President of the AAGL Board of Directors

AAGL – Elevating Gynecologic Surgery
6757 Katella Avenue | Cypress, CA 90630
(800) 554-2245 | (714) 503-6200
By using, you agree that you've read and accept our Privacy Policy.